Sectors
Health, BioTech
Headquarters
Fremont, California, USA
CEO
Elon Musk
Neuralink shares trade at a 189.17% premium to their Series D Valuation, as of Apr 21, 2025. Over the last 90 days, shares returned +12.19%, with $53.5M in secondary bids, offers, and transactions activity, according to PM Insights' secondary market data.
Register today to view the full report, with more in-depth details and analytics
Series D Valuation
Latest funding round
$5.0B
XXXXX
2023-08-01
XX-XX-XXXX
PM Insights Implied Valuation
$14.46B
2025-04-21
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
+189.17%
2023-08-01 ➞ 2025-04-21
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
Low
XXXXX
Business Partnerships
Targeted Impact
Who Will Benefit?
What Comes Next?
No items found.
.png)
Over the last 90 days, shares returned +12.19%, with $53.5M in secondary bids, offers, and transactions activity, according to PM Insights' secondary market data.
PM Insights tracks detailed primary funding rounds and verifies cap table directly from original filings for Neuralink. Neuralink raised $280.0M in its Series D on August 1, 2023, with a price per share reflecting a post-money valuation of $5.0B, according to PM Insights' market data.
Ready to see it in action?
Schedule a demo with one of our experts
